{"id":"W3164781831","doi":"10.1016/s1470-2045(21)00147-9","title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":533,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"Janssen Pharmaceuticals; Pfizer Japan; Genentech; Bavarian Nordic; Merck Sharp and Dohme; Ono Pharmaceutical; European Association of Urology; Bayer Fund; Mirati Therapeutics; Clovis Oncology; Sanofi; GlaxoSmithKline; Merck; Genzyme; Genomic Health; Chugai Pharmaceutical; Roche; Astellas Pharma US; Pfizer; Heron Therapeutics; Bristol-Myers Squibb; AstraZeneca; Boehringer Ingelheim","keywords":"Medicine; Pembrolizumab; Cystoscopy; Bladder cancer; Cystectomy; Cancer; Internal medicine; Clinical endpoint; Surgery; Progressive disease; Urology; Oncology; Clinical trial; Immunotherapy; Disease; Urinary system","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001778634,0.001430724,0.002316004,0.0004151925,0.0003583184,0.001078239,0.0008155567,0.001394679,0.003463795],"category_scores_gemma":[0.0008108423,0.0005257411,0.001680542,0.0004032752,0.0008461967,0.001260069,0.0003286378,0.002985941,0.0009391243],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007554578,"about_ca_system_score_gemma":0.001144382,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008989242,"about_ca_topic_score_gemma":0.002507068,"domain_scores_codex":[0.9996448,0.0001639549,0.00001469986,0.00006065666,0.00003195693,0.00008406435],"domain_scores_gemma":[0.9995462,0.00009818466,0.00008478524,0.00003178404,0.00003177507,0.0002071281],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8424449,0.03517481,0.001982216,0.001875328,0.002474389,0.000177444,0.000205995,0.001551956,0.01756249,0.0003145194,0.00347598,0.09275997],"study_design_scores_gemma":[0.7756351,0.214304,0.005560243,0.00007088485,0.0007301702,0.0001340955,0.00005466065,0.0007502545,0.0009752059,0.0001775427,0.00157886,0.00002892416],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.988684,0.005414134,0.0006050118,0.000563194,0.0002473076,0.001578991,0.0009604404,0.00009785996,0.001849089],"genre_scores_gemma":[0.982862,0.005849948,0.001896887,0.001770997,0.0002949518,0.001819674,0.002152418,0.00003526747,0.003317923],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003463795,"threshold_uncertainty_score":0.01158756,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1191642110718247,"score_gpt":0.4364849762544737,"score_spread":0.3173207651826491,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}